ArticleBMC cancer2026
Long non-coding RNA HOXC-AS3 promotes proliferation and metastasis of esophageal squamous carcinoma by targeting WNT3A through binding to YBX1.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the malignancies with high morbidity and mortality rates. Previous studies have demonstrated the critical roles of long non-coding RNAs (lncRNAs) in cell differentiation, embryonic development and cancer progression. The lncRNA HOXC-AS3 has been shown to exert pro-carcinogenic effects in adenocarcinoma, gastric cancer and breast cancer; however, its biological function in ESCC remains unclear. In the present study, HOXC-AS3 expression was found to be elevated in ESCC tissues. We discovered that HOXC-AS3 regulates the proliferation and migration of ESCC cells. Flow cytometry assays indicated that knockdown of HOXC-AS3 led to increased apoptosis and cell cycle arrest in ESCC cells. RNA sequencing and Gene Ontology findings revealed that the downstream genes regulated by HOXC-AS3 were primarily enriched in signaling pathways associated with cell proliferation and migration. RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (CHIP) experiments confirmed that HOXC-AS3 can be recruited to the promoter region of the WNT3A gene by binding to YBX1. These findings provide evidence of lncRNA HOXC-AS3 functions as a novel oncogene in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.